Amifostine ameliorates recognition memory defect in acute radiation syndrome caused by relatively low-dose of gamma radiation

J Vet Sci. 2010 Mar;11(1):81-3. doi: 10.4142/jvs.2010.11.1.81.

Abstract

This study examined whether amifostine (WR-2721) could attenuate memory impairment and suppress hippocampal neurogenesis in adult mice with the relatively low-dose exposure of acute radiation syndrome (ARS). These were assessed using object recognition memory test, the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay, and immunohistochemical markers of neurogenesis [Ki-67 and doublecortin (DCX)]. Amifostine treatment (214 mg/kg, i.p.) prior to irradiation significantly attenuated the recognition memory defect in ARS, and markedly blocked the apoptotic death and decrease of Ki-67- and DCX-positive cells in ARS. Therefore, amifostine may attenuate recognition memory defect in a relatively low-dose exposure of ARS in adult mice, possibly by inhibiting a detrimental effect of irradiation on hippocampal neurogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Radiation Syndrome / drug therapy
  • Acute Radiation Syndrome / immunology*
  • Acute Radiation Syndrome / psychology
  • Amifostine / pharmacology*
  • Amifostine / therapeutic use
  • Animals
  • Apoptosis / immunology
  • Doublecortin Protein
  • Gamma Rays / adverse effects*
  • Hippocampus / immunology
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Male
  • Memory / radiation effects*
  • Mice
  • Mice, Inbred ICR
  • Neurogenesis / immunology
  • Radiation-Protective Agents / pharmacology*
  • Radiation-Protective Agents / therapeutic use

Substances

  • Dcx protein, mouse
  • Doublecortin Protein
  • Radiation-Protective Agents
  • Amifostine